Oric Pharmaceuticals
Tatyana Profis is an experienced accounting professional with a robust background in managing accounting operations within the pharmaceutical and legal sectors. Currently serving as Accounting Manager at ORIC Pharmaceuticals Inc., Tatyana has streamlined accrual processes and maintained a monthly close calendar. Previous roles include Accounting Manager at Portola Pharmaceuticals, handling R&D accounting and audits, and Corporate Controller at Pearl Therapeutics, overseeing cost accounting procedures and implementing SAP systems. Proficient in financial reporting, month-end close processes, and compliance with Sarbanes-Oxley Act, Tatyana has demonstrated success in improving efficiencies and leading audits throughout a career spanning over three decades, including significant contributions at Morrison & Foerster LLP and Renovis. Tatyana holds a BS in Accounting from San Francisco State University.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.